Month: August 2024

ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has further boosted spider silk production with the introduction of new silk cocoon reeling protocols resulting in higher silk yields.Under the guidance of renowned sericulture expert, Dr. Nirmal Kumar, the Kraig Labs production team modified the processing of its finished silk cocoons, increasing total silk yields per cocoon and improving reeling performance. These mechanical changes to the processing and handling of the Company’s spider silk cocoons resulted in a near doubling of reeling efficiency compared to the prior production runs. “Increasing processing efficiency and cocoon yield was one of Kraig’s top three goals for increasing...

LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that three poster presentations will be delivered on the Company’s product candidates at the American Society of Nephrology (ASN) Kidney Week 2024 taking place October 24-27, 2024 in San Diego, CA. “Data from both oxylanthanum carbonate (OLC) and UNI-494 continue to garner strong interest from the medical community, and we look forward to presenting our data at Kidney Week, one of the most prominent meetings in our field,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive.Title: Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After...

MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT (pronounced “limelight”) clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Expanding the clinical trial to Canada is significant as it will provide an opportunity to reach a broader patient population encompassing many gene mutations associated with RP,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. “The Health Canada trial will run in parallel with the U.S. FDA trial, expediting the ability to potentially...

Jorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D. to Review CLOVER WaM Pivotal Study FLORHAM PARK, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced two presentations: one regarding the treatment of a patient with Bing-Neel Syndrome (BNS), and a review of the company’s CLOVER WaM pivotal study of iopofosine I 131 at the 12th International Workshop on Waldenstrom’s Macroglobulinemia being held October 17-19, 2024, in Prague, Czech Republic. BNS is a rare, life-threatening complication of WM that manifests in the central nervous system (CNS). It typically translates into various neurological...

GUANGZHOU, China, Aug. 26, 2024 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: FANH) (the “Company” or “Fanhua”), a leading independent technology-driven financial services provider in China, today announced that the Company expects to release its unaudited financial results for the first half of 2024 on September 18, 2024. The Company expects its adjusted EBITDA for the first half of 2024 to be in the range of RMB70 million to RMB80 million. About Fanhua Established in Guangzhou in 1998 and listed on NASDAQ in 2007 (Nasdaq: FANH), Fanhua is a leading independent financial services provider in China with strong technology capabilities and a commitment to empowering financial advisors and fostering sustained value creation for customers. Our mission revolves around creating an inclusive and collaborative platform for independent financial...

MONTREAL, Aug. 26, 2024 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX.V: FPC) (“Falco” or the “Corporation”) is pleased to announce the creation and establishment of Technical and Strategic Committees (collectively the “Committees”), as contemplated by the terms of the Operating Licence and Indemnity Agreement (“OLIA”) concluded with Glencore Canada Corporation (“Glencore”) on January 23, 2024. The creation of the Committees confirms the parties’ recognition that the successful development, construction, operation and closure of the Falco Horne 5 Project in a manner that ensures the safety and operational integrity of the Horne Smelter operations, requires coordination and communication between Falco and Glencore at multiple levels. Technical Committee The Technical Committee will focus among others, on determining ongoing operating...

A presentation of Kaldvik AS interim report Q2 2024 will be held at 11:00 (CET)/ 09:00 Icelandic time on the 29th of August 2024. The company’s CEO Guðmundur Gíslason and CFO Róbert Róbertsson will be presenting the company’s results. This session will be held in English via Teams. Questions may be asked after the session. Join the session by using this link: https://t.ly/-E3AP Kaldvik AS interim report Q2 2024 will be released on the 29th August 2024 at 7:00 (CET). Contacts: Róbert Róbertsson, CFO of Kaldvik AS: +354 843 0086 (mobile)This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Reference is made to the notice on 20 August 2024 regarding a private placement of 16.2 million shares at NOK 0.60 per share. The share capital has been registered and the shares will be delivered soonest. Following the issue, the company’s share capital is NOK 49,443,983.25 divided into 329,626,555 shares, each with a nominal value of NOK 0.15. As of today, 326,722,294 shares are tradeable. 2,904,261 shares are issued on a separate ISIN and will be tradeable upon approval of a listing prospectus. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring...

On 26 August 2024, AS Merko Ehitus Eesti, part of AS Merko Ehitus group, and GRK Eesti AS signed a design and construction contract with OÜ Rail Baltic Estonia for the construction of the fourth stage of Rail Baltica Harjumaa main line railway infrastructure on Saku-Harjumaa border section. The contract includes the construction of approximately 10.5 kilometres of railway embankment, together with accompanying facilities, noise barriers, maintenance and access roads. In carrying out the works, AS Merko Ehitus Eesti is the leading partner with a 51:49 ratio. The contract value is approximately EUR 59.9 million, plus value added tax. The duration of the construction works is 48 months. AS Merko Ehitus Eesti (merko.ee) is a recognised Estonian construction company, which offers construction services in general construction, civil engineering...